Rush University Medical Center (RUMC) and Cook County Health (CCH) have cared for over two thousand patients with COVID-19 infections since the beginning of the pandemic in January 2020. During the first surge of infections in Chicago, Rush University Infectious Diseases launched an additional three COVID-19 services at RUMC to treat the seriously and critically ill patients admitted to the hospital. ID fellows participated in clinical care and provided vital infection control as well as testing assistance at RUMCH and Stroger Hospital. During this time, ID faculty at Cook County Health and RUMC led or participated in multiple epidemiologic studies, diagnostic investigations, and clinical trials of vaccines and therapeutics. ID fellows participated in these activities, including by providing essential assessments of study patients. 

ID fellows were instrumental in developing and updating infectious diseases treatment guidance that is applied across RUMC and CCH. The guidance documents are evidence-based, and, given the rapid evolution of information on diagnosis, treatment, and prevention, are updated regularly to keep abreast of new data.  


Selected COVID-19 studies with fellow involvement are listed below; fellows’ names are shown in bold type. 

  1. Sansom SE, Barbian H, Snitkin ES, Fukuda C, Moore NM, Thotapalli L, Baied EJ, Kim DY, Hayden MK, Lin MY; and for the Centers for Disease Control and Prevention Epicenter Program. Genomic Investigation to Identify the Source of SARS-CoV-2 Infection Among Healthcare Personnel from Symptomatic Patients and Staff in an Acute Care Hospital. Oral abstract presentation. SHEA Spring 2022. Colorado Springs, CO. 
  2. Kim DY, Lin MY, Jennings C, Li H, Jung JH, Moore NM, Ghinai I, Black SR, Zaccaro DJ, Brofman J, Hayden MK and for the CDC Prevention Epicenter Program. Duration of replication-competent SARS-CoV-2 shedding among patients with severe or critical coronavirus disease 2019 (COVID-19). Clin Infect Dis May 24, 2022; ciac405. ePub ahead of print

Selected multicenter COVID-19 clinical treatment trials: 

  1. Healthcare Worker Exposure Responses and Outcomes of Hydroxychloroquine Trial (HERO-HCQ) (in process). Elias Baied, MD, Beverly Sha, MD, Carlos Santos, MD, Ajay Sood, MD, Kimberly Blanchard, NP, Raj Shah MD, Yoona Rhee, MD.  
  2. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia.  
    Site PI: Mariam Aziz, MD
  3. A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19 
    Conducted at RUMC, site PI Shivanjali Shankaran, MD,  and CCHS, site PI Gregory Huhn, MD
  4. A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment 
    Conducted at RUMC, site PI Shivanjali Shankaran, MD,  and CCHS, site PI Gregory Huhn, MD
  5. A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19 (ACTIV-4). Conducted at CCH, site PI Dr. Katayoun Rezai, MD
  6. A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTIV-5). Conducted at CCH, site PI Dr. Audrey French, MD 
  7. The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID). Conducted at CCH, site PIs Gregory Huhn, Katayoun Rezai.
  8. Adaptive Platform Treatment Trial for Outpatients With COVID-19 (ACTIV-2). Conducted at CCH, site PI Monica Mercon, MD, PhD
  9. A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (BLAZE-1). Conducted at CCH, site PI Gregory Huhn, MD, MPHTM. 

Other selected COVID-19 studies conducted at CCHS:  

  1. Inpatient and outpatient testing of COVID 19 at John H. Stroger, Jr Hospital of Cook County. from March 2, 2020 to present: Screening rates, positive testing and disease related outcomes. Katayoun Rezai, MD 
  2. Tocilizumab for COVID-19-related disease: assessing clinical correlates and response to treatment. Ronald Lubelchek, MD 
  3. . Disparities in COVID-19 prevention due to a lack of social distancing in the Hispanic/ Latinx population. Sheila Badri, MD 
  4. HVTN 405/HPTN 1901 - Characterizing SARS-CoV-2-specific immunity in convalescent individuals. Temitope Oyedele, MD 
  5. Genomic Epidemiology of COIVD-19 in Jail. Kyle Popovich, MD